Serum institute submits data from trials of vaccine

NEW DELHI: Pune-based Serum Institute of India (SII) has submitted additional updated data from clinical trials of Covishield sought by the drug regulator’s panel evaluating Covid vaccine applications for emergency use authorisation, official sources said, reports Sushmi Dey.
The Subject Expert Committee (SEC) on Covid vaccine under the Drugs Controller General of India had asked Bharat Biotech and SII to produce updated data from ongoing clinical trials in India.
The latest development may once again set the clock ticking for the launch of the vaccine, as the government is expecting to roll out vaccination against Covid-19 by mid-January.